Osteoprotegerin.
Izabela Krieger, Grażyna Odrowąż‐Sypniewska
Abstract
Izabela Krieger, Grażyna Odrowąż‐Sypniewska
Abstract
In 1997, a glycoprotein was isolated that blocked osteoclast differentiation from precursor cells. This protein prevented osteoporosis when administered to ovariectomized rats, and led to osteopetrosis when overexpressed. This newly discovered protein was named osteoprotegerin (OPG). The discovery of osteoprotegerin has stimulated a great deal of work in the fields of endocrinology, rheumatology and immunology, and resulted in the further discovery of two other members of the TNF receptor superfamily: the receptor activator of nuclear factor Kss (RANK) and osteoprotegerin ligand (OPG-L or RANKL). To date, however, relatively little is still known about OPG/ RANKL/ RANK.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In 1997, a glycoprotein was isolated that blocked osteoclast differentiation from precursor cells. This protein prevented osteoporosis when administered to ovariectomized rats, and led to osteopetrosis when overexpressed. This newly discovered protein was named osteoprotegerin (OPG). The discovery of osteoprotegerin has stimulated a great deal of work in the fields of endocrinology, rheumatology and immunology, and resulted in the further discovery of two other members of the TNF receptor superfamily: the receptor activator of nuclear factor Kss (RANK) and osteoprotegerin ligand (OPG-L or RANKL). To date, however, relatively little is still known about OPG/ RANKL/ RANK.
Key concepts: Osteoprotegerin, RANKL, RANK Ligand, Internal medicine, Osteoclast, Osteopetrosis, Endocrinology, Receptor